Cargando…

Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases

SIMPLE SUMMARY: The antitumor effect of immune checkpoint inhibitors (ICIs) such as antibodies against CTLA-4, PD-1, and PD-L1 is higher than that of conventional chemotherapy and is durable, improving the survival of patients with advanced head and neck squamous cell carcinoma (HNSCC). However, thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yura, Yoshiaki, Hamada, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834130/
https://www.ncbi.nlm.nih.gov/pubmed/35159059
http://dx.doi.org/10.3390/cancers14030792
_version_ 1784649108672217088
author Yura, Yoshiaki
Hamada, Masakazu
author_facet Yura, Yoshiaki
Hamada, Masakazu
author_sort Yura, Yoshiaki
collection PubMed
description SIMPLE SUMMARY: The antitumor effect of immune checkpoint inhibitors (ICIs) such as antibodies against CTLA-4, PD-1, and PD-L1 is higher than that of conventional chemotherapy and is durable, improving the survival of patients with advanced head and neck squamous cell carcinoma (HNSCC). However, this therapy reduces the immune tolerance state and allows antitumor cytotoxic CD8(+) T cells to attack normal cells expressing self-antigens that cross-react with tumor antigens, and so it can induce immune-related adverse events (irAEs). Treatment of various malignancies, including HNSCC, with ICIs may result in the appearance of oral irAEs. In the oral cavity, irAEs such as Sicca syndrome, oral lichenoid reaction (OLR), and pemphigoid occur. It is necessary to elucidate the pathogenic mechanisms of these intractable diseases. Early diagnosis and appropriate approaches to irAE are needed for efficient treatment of advanced HNSCC by ICIs. ABSTRACT: Conventional chemotherapy and targeted therapies have limited efficacy against advanced head and neck squamous cell carcinoma (HNSCC). The immune checkpoint inhibitors (ICIs) such as antibodies against CTLA-4, PD-1, and PD-L1 interrupt the co-inhibitory pathway of T cells and enhance the ability of CD8(+) T cells to destroy tumors. Even in advanced HNSCC patients with recurrent diseases and distant metastasis, ICI therapy shows efficiency and become an effective alternative to conventional chemotherapy. However, as this therapy releases the immune tolerance state, cytotoxic CD8(+) T cells can also attack organs and tissues expressing self-antigens that cross-react with tumor antigens and induce immune-related adverse events (irAEs). When patients with HNSCC are treated with ICIs, autoimmune diseases occur in multiple organs including the skin, digestive tract, endocrine system, liver, and respiratory tract. Treatment of various malignancies, including HNSCC, with ICIs may result in the appearance of oral irAEs. In the oral cavity, an oral lichenoid reaction (OLR) and pemphigoid develop. Sicca syndrome also occurs in association with ICIs, affecting the salivary glands to induce xerostomia. It is necessary to elucidate the pathogenic mechanisms of these intractable diseases that are not seen with conventional therapy. Early diagnosis and appropriate approaches to irAEs are needed for efficient treatment of advanced HNSCC by ICIs.
format Online
Article
Text
id pubmed-8834130
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88341302022-02-12 Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases Yura, Yoshiaki Hamada, Masakazu Cancers (Basel) Review SIMPLE SUMMARY: The antitumor effect of immune checkpoint inhibitors (ICIs) such as antibodies against CTLA-4, PD-1, and PD-L1 is higher than that of conventional chemotherapy and is durable, improving the survival of patients with advanced head and neck squamous cell carcinoma (HNSCC). However, this therapy reduces the immune tolerance state and allows antitumor cytotoxic CD8(+) T cells to attack normal cells expressing self-antigens that cross-react with tumor antigens, and so it can induce immune-related adverse events (irAEs). Treatment of various malignancies, including HNSCC, with ICIs may result in the appearance of oral irAEs. In the oral cavity, irAEs such as Sicca syndrome, oral lichenoid reaction (OLR), and pemphigoid occur. It is necessary to elucidate the pathogenic mechanisms of these intractable diseases. Early diagnosis and appropriate approaches to irAE are needed for efficient treatment of advanced HNSCC by ICIs. ABSTRACT: Conventional chemotherapy and targeted therapies have limited efficacy against advanced head and neck squamous cell carcinoma (HNSCC). The immune checkpoint inhibitors (ICIs) such as antibodies against CTLA-4, PD-1, and PD-L1 interrupt the co-inhibitory pathway of T cells and enhance the ability of CD8(+) T cells to destroy tumors. Even in advanced HNSCC patients with recurrent diseases and distant metastasis, ICI therapy shows efficiency and become an effective alternative to conventional chemotherapy. However, as this therapy releases the immune tolerance state, cytotoxic CD8(+) T cells can also attack organs and tissues expressing self-antigens that cross-react with tumor antigens and induce immune-related adverse events (irAEs). When patients with HNSCC are treated with ICIs, autoimmune diseases occur in multiple organs including the skin, digestive tract, endocrine system, liver, and respiratory tract. Treatment of various malignancies, including HNSCC, with ICIs may result in the appearance of oral irAEs. In the oral cavity, an oral lichenoid reaction (OLR) and pemphigoid develop. Sicca syndrome also occurs in association with ICIs, affecting the salivary glands to induce xerostomia. It is necessary to elucidate the pathogenic mechanisms of these intractable diseases that are not seen with conventional therapy. Early diagnosis and appropriate approaches to irAEs are needed for efficient treatment of advanced HNSCC by ICIs. MDPI 2022-02-04 /pmc/articles/PMC8834130/ /pubmed/35159059 http://dx.doi.org/10.3390/cancers14030792 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yura, Yoshiaki
Hamada, Masakazu
Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases
title Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases
title_full Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases
title_fullStr Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases
title_full_unstemmed Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases
title_short Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases
title_sort oral immune-related adverse events caused by immune checkpoint inhibitors: salivary gland dysfunction and mucosal diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834130/
https://www.ncbi.nlm.nih.gov/pubmed/35159059
http://dx.doi.org/10.3390/cancers14030792
work_keys_str_mv AT yurayoshiaki oralimmunerelatedadverseeventscausedbyimmunecheckpointinhibitorssalivaryglanddysfunctionandmucosaldiseases
AT hamadamasakazu oralimmunerelatedadverseeventscausedbyimmunecheckpointinhibitorssalivaryglanddysfunctionandmucosaldiseases